The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor - The efficacy and safety of direct renin inhibitor aliskiren on the blood glucose control of DPP-IV inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004925

Enrollment

Registered

2011-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus hypertension

Interventions

direct renin inhibitor aliskiren amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who showed written informed consent to take part in this trial 2. Ptients who take ACE inhibitor or ARB for 3 months or longer 3. Ptients who take DPP-IV inhibitor for 3 months or longer 4. Patients whose HbA1c is between 5.8% and 7% 5. Patients who cannnot achieve the blood pressure treatment goal of 130/80 mmHg

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes mellitus 2. Patients who take both ACE inhibitor and ARB 3. Ptients who have allergy to the study drugs 4. Severe hypertension (180/110 mmHg or higher) 5. Pregnant women, women who want to be pregnant 6. Patients taking cyclosporine 7. Sever liver dysfunction (GOT>80 IU/L, GPT>80 IU/L), renal dysfunction (Cr>1.5(male), 1.4 (female) mg/dl)

Design outcomes

Primary

Measure	Time frame
The value of HbA1c at the endopoitn of the trial	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026